Sign in

    RK

    Managing Director and Senior Healthcare Analyst at HC Wainright

    Raghuram Selvaraju, Ph.D., is a Managing Director and Senior Healthcare Analyst at H.C. Wainwright, focusing on healthcare sector research, particularly in biotechnology, pharma, and related industries. He has covered and published on a broad range of companies across drug development, with demonstrated success including rankings by StarMine for earnings accuracy and recognition in The Wall Street Journal’s Best on the Street Analyst awards for stock-picking performance. With more than a decade of experience, Dr. Selvaraju previously held senior research roles at MLV & Co., Aegis Capital, Hapoalim Securities USA, and Rodman & Renshaw before joining H.C. Wainwright. He holds a Ph.D. in molecular neuroscience and cellular immunology, an M.S. in molecular biology from the University of Geneva, and an MBA from Cornell University.

    RK's questions to CollPlant Biotechnologies (CLGN) leadership

    RK's questions to CollPlant Biotechnologies (CLGN) leadership • Q4 2024

    Question

    The analyst inquired about the timeline for updates and potential milestone payments from the AbbVie collaboration, as well as the market potential and expected revenue flow from the expanded distribution of the Vergenix product.

    Answer

    The company stated that the timeline for the AbbVie program is determined by AbbVie, and they cannot estimate future milestone payments. Regarding Vergenix, the product targets the tendinopathy market, and the company is establishing distribution networks in Europe and Asia, hoping to see sales in the next year after securing regulatory approvals.

    Ask Fintool Equity Research AI

    RK's questions to HOOKIPA Pharma (HOOK) leadership

    RK's questions to HOOKIPA Pharma (HOOK) leadership • Q4 2021

    Question

    RK from H.C. Wainwright inquired about the expected content of the four upcoming presentations at the AACR conference. He also asked about the development plan and timeline for the HB-700 KRAS program and whether its progress is contingent on milestones from the HB-200 or HB-300 programs.

    Answer

    Igor Matushansky, CMO & Global Head of R&D, stated the AACR presentations will cover preclinical, translational, and biomarker data, including updates on the prostate cancer (HB-300) and HB-200 programs. He confirmed the HB-700 program is not dependent on further clinical data from other assets and will proceed once manufacturing is ready. CEO Joern Aldag clarified the IND filing for HB-700 is anticipated in 2023 or beyond.

    Ask Fintool Equity Research AI